Key result
Higher monocyte IL-1α expression links to increased atherosclerotic risk, driving vascular adhesion and inflammation.
Why the study?
Does IL-1\u0alpha inhibition reduce leukocyte-endothelial adhesion and inflammation in acute myocardial infarction and chronic kidney disease?
Does IL-1\u0alpha inhibition reduce leukocyte-endothelial adhesion and inflammation in acute myocardial infarction and chronic kidney disease?
Answers are grounded in this paper and cite their sources.
IL-1\u0alpha is a key mediator of leukocyte-endothelial adhesion and inflammation in AMI and CKD, suggesting its inhibition may serve as a novel anti-inflammatory treatment strategy.
BACKGROUND: Cardiovascular diseases and chronic kidney disease (CKD) are highly prevalent, aggravate each other, and account for substantial mortality. Both conditions are characterized by activation of the innate immune system. The alarmin interleukin-1α (IL-1α) is expressed in a variety of cell types promoting (sterile) systemic inflammation. The aim of the present study was to examine the role of IL-1α in mediating inflammation in the setting of acute myocardial infarction (AMI) and CKD. METHODS: mice and investigated the underlying mechanisms in vitro in monocytes and endothelial cells. RESULTS: IL-1α is strongly expressed on the surface of monocytes from patients with AMI and CKD compared with healthy controls. Higher IL-1α surface expression on monocytes from patients with AMI and CKD was associated with a higher risk for atherosclerotic cardiovascular disease events, which underlines the clinical relevance of IL-1α. In mice, IL-1α, but not IL-1β, mediates leukocyte-endothelial adhesion as determined by intravital microscopy. IL-1α promotes accumulation of macrophages and neutrophils in inflamed tissue in vivo. Furthermore, IL-1α on monocytes stimulates their homing at sites of vascular injury. A variety of stimuli such as free fatty acids or oxalate crystals induce IL-1α surface expression and release by monocytes, which then mediates their adhesion to the endothelium via IL-1 receptor-1. IL-1α also promotes expression of the VCAM-1 (vascular cell adhesion molecule-1) on endothelial cells, thereby fostering the adhesion of circulating leukocytes. IL-1α induces inflammatory injury after experimental AMI, and abrogation of IL-1α prevents the development of CKD in oxalate or adenine-fed mice. CONCLUSIONS: IL-1α represents a key mediator of leukocyte-endothelial adhesion and inflammation in AMI and CKD. Inhibition of IL-1α may serve as a novel anti-inflammatory treatment strategy.
No takes yet. Share an insight, caveat, or question.
Schunk et al. (2021) studied Acute myocardial infarction (AMI) and chronic kidney disease (CKD). Interleukin-1α (IL-1α) vs. Healthy controls was evaluated on Leukocyte-endothelial adhesion and inflammation. Higher IL-1α surface expression on monocytes in AMI and CKD is associated with increased atherosclerotic event risk and mediates leukocyte-endothelial adhesion and inflammation.
Synapse has enriched 10 related papers. Consider them for comparative context: